<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28792/keynote-240-in-1st-line-hcc-outcome?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

KEYNOTE-240 in 1st Line HCC Outcome

Name: KEYNOTE-240 in 1st Line HCC Outcome
Uploaded: 2019-06-27T07:01:32
Duration: 2 min 54 s
Description: Richard S. Finn, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California explains the outcomes of hepatocellular carcinoma (HCC) in KEYNOTE-240 which compares pembrolizumab versus placebo in 1st line HCC.

00:02:54

Don

3 years 323 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28792/keynote-240-in-1st-line-hcc-outcome?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/28792/keynote-240-in-1st-line-hcc-outcome?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/28792/keynote-240-in-1st-line-hcc-outcome?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/28792?channelName=obr"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190627190132_ffb1/video_190627190132_ffb1.jpg?cache=15669161351678829655">KEYNOTE-240 in 1st Line HCC Outcome</a>

Link (BBCode):

[url=https://oncologytube.com/v/28792?channelName=obr][img]https://oncologytubecom.cdn.ypt.me/videos/video_190627190132_ffb1/video_190627190132_ffb1.jpg?cache=15669161351678829655[/img]KEYNOTE-240 in 1st Line HCC Outcome[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Other

Description:

Richard S. Finn, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California explains the outcomes of hepatocellular carcinoma (HCC) in KEYNOTE-240 which compares pembrolizumab versus placebo in 1st line HCC.